Document ID: chunk:federal_register_of_legislation:F2018L01746:clause:2_19
Version: federal_register_of_legislation:F2018L01746
Segment Type: clause
Provision Reference: sch 2 cl 19
Character Range: 30253–31835

19                                       updated                                         date that the entry was last updated

In this Part:
  low impact, in relation to a shortage of a medicine that is not of critical impact, means a shortage that is assessed as low patient impact in accordance with the assessment framework set out in the Medicine Shortages Information Initiative: Protocol for all Australian Sponsors and the Therapeutic Goods Administration published in May 2014.
  medium impact, in relation to a shortage of a medicine that is not of critical impact, means a shortage that is assessed as medium patient impact in accordance with the assessment framework set out in the Medicine Shortages Information Initiative: Protocol for all Australian Sponsors and the Therapeutic Goods Administration published in May 2014.
Note:  The Medicine Shortages Information Initiative: Protocol for all Australian Sponsors and the Therapeutic Goods Administration can be found on the internet (and viewed for free) on the internet at http://www.tga.gov.au.

Part 4—Information relating to a decision to permanently discontinue the supply of a medicine that was made before 1 January 2019

For each item in column 1 of the following table, the kind of therapeutic goods information specified in column 2 has the description given in column 3.

Kinds of  therapeutic goods information
Column 1                                 Column 2                                    Column 3

Item                                     Information                                 Description